Suppr超能文献

荧光标记的抑制蛋白的细胞分布为筛选G蛋白偶联受体提供了一种强大、灵敏且通用的检测方法。

The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors.

作者信息

Oakley Robert H, Hudson Christine C, Cruickshank Rachael D, Meyers Diane M, Payne Richard E, Rhem Shay M, Loomis Carson R

机构信息

Norak Biosciences, Inc, Research Triangle Park, NC, USA.

出版信息

Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):21-30. doi: 10.1089/154065802761001275.

Abstract

G protein-coupled receptors (GPCRs) have proven to be a rich source of therapeutic targets; therefore, finding compounds that regulate these receptors is a critical goal in drug discovery. The Transfluor technology utilizes the redistribution of fluorescently labeled arrestins from the cytoplasm to agonist-occupied receptors at the plasma membrane to monitor quantitatively the activation or inactivation of GPCRs. Here, we show that the Transfluor technology can be quantitated on the INCell Analyzer system (INCAS) using the vasopressin V(2) receptor (V(2)R), which binds arrestin with high affinity, and the beta(2)-adrenergic receptor (beta(2)AR), which binds arrestin with low affinity. U2OS cells stably expressing an arrestin-green fluorescent protein conjugate and either the V(2)R or the beta(2)AR were plated in 96-well plastic plates and analyzed by the INCAS at a screening rate of 5 min per plate. Agonist dose-response and antagonist dose-inhibition curves revealed signal-to-background ratios of approximately 25:1 and 8:1 for the V(2)R and beta(2)AR, respectively. EC(50) values agreed closely with K(d) values reported in the literature for the different receptor agonists. In addition, small amounts of arrestin translocation induced by sub-EC(50) doses of agonist were distinguished from the background noise of untreated cells. Furthermore, differences in the magnitude of arrestin translocation distinguished partial agonists from full agonists, and Z' values for these ligands were >0.5. These data show that the Transfluor technology, combined with an automated image analysis system, provides a direct, robust, and universal assay for high throughput screening of known and orphan GPCRs.

摘要

G蛋白偶联受体(GPCRs)已被证明是丰富的治疗靶点来源;因此,寻找调节这些受体的化合物是药物研发中的关键目标。Transfluor技术利用荧光标记的抑制蛋白从细胞质重新分布到质膜上激动剂占据的受体,来定量监测GPCRs的激活或失活。在此,我们表明,使用与抑制蛋白具有高亲和力的血管加压素V(2)受体(V(2)R)以及与抑制蛋白具有低亲和力的β(2)肾上腺素能受体(β(2)AR),可以在INCell分析仪系统(INCAS)上对Transfluor技术进行定量分析。将稳定表达抑制蛋白-绿色荧光蛋白偶联物以及V(2)R或β(2)AR的U2OS细胞接种到96孔塑料板中,并通过INCAS以每板5分钟的筛选速度进行分析。激动剂剂量-反应曲线和拮抗剂剂量-抑制曲线显示,V(2)R和β(2)AR的信号与背景比值分别约为25:1和8:1。EC(50)值与文献中报道的不同受体激动剂的K(d)值密切相符。此外,由低于EC(50)剂量的激动剂诱导的少量抑制蛋白易位与未处理细胞的背景噪声得以区分。此外,抑制蛋白易位幅度的差异区分了部分激动剂和完全激动剂,并且这些配体的Z'值>0.5。这些数据表明,Transfluor技术与自动图像分析系统相结合,为已知和孤儿GPCRs的高通量筛选提供了一种直接、可靠且通用的检测方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验